Interview
with Neil Love, MD Breast Cancer Update for Medical Oncologists,
Program 6 2000
Play
Audio Below:
Dr.
Osborne: I think we’re going to have a little bit of a dilemma,
and maybe several choices. It looks like the aromatase inhibitors
are a little bit better than tamoxifen, and so could they arguably
be first-line therapy? Arimidex is now approved for first-line therapeutic
metastatic disease. Maybe letrozole will be, too.
Dr.
Love: Are you currently using Arimidex or using aromatase inhibitors
as first-line?
Dr.
Osborne: I do, particularly in patients who have had prior tamoxifen
adjuvant therapy.
Dr.
Love: What about choosing an aromatase inhibitor right now? How
do you see the three that are available and how do you make that
choice?
Dr.
Osborne: I think they’re all probably pretty good. I can’t
see any major differences between them. I guess I got in the habit
of writing Arimidex, because it came out first. I think any one
of those is. I just happen to have most of my experience with Arimidex.
Dr.
Love: Again, getting back to clinical decision-making. I’m
sure it’s going to take a while to sort of shake out. But assuming
Faslodex is available and you had a postmenopausal women who was
presenting with metastatic breast cancer, where you wanted to use
hormonal therapy, any thoughts about how you would choose between
tamoxifen, an aromatase inhibitor and Faslodex?
Dr.
Osborne: I would probably, if they were all three available today
and all I knew about them was what I know today, I would probably
choose Faslodex. I don’t think it would be a particular mistake
to try Arimidex or letrozole, and maybe it’s not even a mistake
to go with tamoxifen first and give it a try and then, when those
patients progress, then go with these therapies. My guess is, from
a survival point of view, it may in the end not make much difference.
But, if I have to look at them today – to me – maybe Faslodex
is slightly better, based on the results of this one trial, showing
a significant prolongation of the duration of response in responding
patients.
Formestane
is feasible and effective in elderly breast cancer patients with
comorbidity and disability. Venturino,
A.; Comandini, D.; Granetto, C.; Audisio, R. A.; Castiglione, F.;
Rosso, R., and Repetto, L. (Reprint available from: Venturino A
PO S Lazzaro, Via P Belli 26 I-12051 Alba CN Italy). Breast Cancer
Research & Treatment. 62(3):217-222, 2000 Aug. In process
Critique
of survival update analysis from two phase III anastrozole clinical
trials. Buzdar, A. U.; Wood; Wolter; Vogel; Bland, and Ravdin. Annals
of Surgical Oncology. 6(8 Suppl S):8S-11S, 1999 Dec. No abstract
Letrozole:
Which dose to be used? Buzdar, A. U. Journal of Clinical Oncology. 18(8):1802-1803,
2000 Apr. No abstract
Similarities
and distinctions in the mode of action of different classes of antioestrogens
[Review]. Wakeling,
A. E. Endocrine-Related Cancer. 7(1):17-28, 2000 Mar. No abstract
Approaches
targeted to estrogen receptors for treatment of tamoxifen-resistant
breast cancer: A brief overview. Terakawa, N. (Reprint available from: Terakawa N Tottori Univ,
Sch Med, Dept Obstet & Gynecol Yonago Tottori 683 Japan)..
Oncology. 59(Suppl 1):3-4, 2000. No abstract
Treatment
with the pure antiestrogen faslodex (ICI 182780) induces tumor necrosis
factor receptor 1 (TNFR1) expression in MCF-7 breast cancer cells. Smolnikar,
K.; Loffek, S.; Schulz, T.; Michna, H., and Diel, P. (Reprint available
from: Smolnikar K DSHS Cologne, Inst Morphol & Tumor Res Carl
Diem Weg 6 D-50927 Cologne Germany). Breast Cancer Research &
Treatment. 63(3):249-259, 2000 Oct. In process
Symposium
overview: Estrogens and antiestrogens in managing the patient with
breast cancer. Newman,
L. A.; Wood, W. C.; Sellin, R. V.; Morrow, M.; Vogel, C., and Singletary,
S. E (Reprint available from: Singletary SE Univ Texas, MD Anderson
Canc Ctr, Dept Surg Oncol 1515 Holcombe Blvd,Box 106 Houston, TX
77030 USA).. Annals of Surgical Oncology. 7(8):568-574, 2000 Sep.
In process
